Hi Ahmed, are you referring to the pipeline mentioned by the company, below?
Positive results for DMX-200 would go some way to proving that Dimerix's Receptor HIT drug discovery platform is effective and likely to be effective again in these areas. I agree it would be good to out-licence DMX-200 and then work on the program below. It's a solid pipeline.
Ann: Shareholder Briefing, page-85
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.005(1.25%) |
Mkt cap ! $223.0M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 41.0¢ | 38.5¢ | $758.5K | 1.897M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20986 | 40.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.0¢ | 110235 | 2 |
View Market Depth
| Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |